Member Info for Cliveas

To come when US opens as listed on Nasdaq! Wednesday promises to be very good

Feel free to ramp! I have taken two holdings. One longer term the other with a target price 250+ Very new to this so any info you have and can share I would be grateful. So far off the radar it is unreal. GL.

Ask out at 175 I think a return to 250+ is not out of the question. Think I am in before the news has sunk in. Results and more info to come on wednesday. GL

Drug delivery specialist Midatech (LON:MPTH) will commercially launch Zuplenz, its anti-vomiting drug for chemo and radiotherapy patients, in the US this week. Midatech acquired the treatment from Galena Biopharma in December for a consideration heavily weighted towards future sales. Since then, it has beefed up its sales, marketing and administrative staff ahead of the launch. Jim Phillips, Midatech’s chief executive, said Zuplenz offers relief from some of the most debilitating side-effects of common cancer treatments. Generically called ondansetron, the oral soluble film eases the problem of gritty residue, having to wear a patch and sedative side effects. Zuplenz also leverages Midatech’s existing commercial infrastructure in the US, he added. In 2015, more than 20mln prescriptions were written in the US alone for ondansetron, half of which were oral dissolving tablets. The market is huge and also hugely beneficial.

Never heard of it until today! broker targets 423! Results to exceed expectations on Wednesday! The more I dig the more I like!

According to data from Symphony Health Solutions, there were approximately twenty million prescriptions written in 2015 in the US for ondansetron, with more than half of the ondansetron market being fulfilled with oral dissolving tablets. Zuplenz's unique profile and benefits, combined with both excellent commercial reimbursement and Midatech Pharma's zero-dollar out-of-pocket patient co-pay program (for qualifying individuals) provides a strong and proven platform to launch Zuplenz® into the US market. David Benharris, MTPUS President, said: "We are very excited to add a unique and proven CINV/RINV product to our oncology supportive care portfolio. The planned growth of our commercial organisation in support of the Zuplenz launch allows us to add significant share of voice amongst the leading writers of oncology supportive care products, while further strengthening and expanding upon our relationships in these important offices."

Midatech's Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US - Midatech further expands its commercial footprint in US, supporting the Zuplenz® launch Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces its forthcoming full commercial launch of Zuplenz® (ondansetron) Oral Soluble Film to prevent post-operative, chemotherapy and radiation-induced nausea and vomiting, in the United States. In support of the Zuplenz product launch and Midatech's growing oncology supportive care portfolio, Midatech has invested in a significant expansion of its commercial organization, including additional field sales representation, field sales management, national accounts personnel, and marketing and internal support staff. Midatech's newly expanded commercial team will attend the Zuplenz launch meeting Tuesday to Friday of this week in Dallas, Texas. Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "Zuplenz is a valuable treatment option that offers convenient relief from one of the most debilitating side-effects of common cancer treatments. The product launch of Zuplenz represents yet another step forward for Midatech and further leverages our commercial infrastructure in the US. Zuplenz is a perfect example of our rapidly growing portfolio of marketed oncology products and will further contribute to our growing revenue stream." Zuplenz, acquired into Midatech's portfolio of marketed oncology products in December 2015, is a 5HT3 receptor antagonist. The novel oral soluble film technology used by Zuplenz offers an innovative approach to ondansetron delivery that, in comparison to other delivery methods, provides several key cancer patient benefits including a non-gritty delivery mechanism, non-patch delivery, discreet on-the-go usage, removal of the burden of swallowing pills during emesis, and no sedative side effects. Jerilyn Arnold, Senior RN, Oncology Nurse Specialist at Texas Oncology, said: "In practice, patients often find non-tablet therapies for CINV and RINV sub-optimal due to gritty residue, potential need for the patient to wear a patch and possible exacerbation of their nausea and vomiting due to various other product characteristics. Together, these limitations contribute to reduced compliance and efficacy often leading to various morbidities associated with CINV and RINV. Zuplenz provides an excellent localised therapy solution for the treatment of both CINV and RINV because the novel formulation avoids the pitfalls that come with other ondansetron products." According to data from Symphony Health Solutions, there were approximately twenty million prescriptions written in 2015 in the US for onda

Price recently hit by overhang of shareholders selling from merged company. Results expected on wednesday to be ahead of expectations. Launch of Zuplenz in Us over next four days which in their words : Zuplenz®, launched in the United States in July 2015, is an anti-emetic, which does not need to be injected or swallowed, offering patients a differentiated alternative. Midatech expects that the acquisition of Zuplenz® will leverage its commercial infrastructure in the United States, following the acquisition of DARA BioSciences, and is complementary to Midatech's three existing marketed oncology products. With patent protection until at least 2029, Zuplenz® is targeting an estimated $4.6bn market by 20181 and is expected to add to Midatech's growing revenues. listed on Nasdaq and currently above this price in US. Whats not to like?

Something stirring more good news to come?

Can only be a good thing with less dilution and revenues kicking sooner than thought and you can still buy in cheaper! On 21 March 2016, GAN announced that it had raised gross proceeds of approximately £3.1 million by way of a placing of a total of 11,069,326 new Ordinary Shares at a Placing Price of 28 pence per Placing Share (the "Placing"). The Company has reviewed its ongoing working capital requirements and believes that a reduced amount will be sufficient for its present requirements and will result in lower dilution for non-participating shareholders. The Placing has been adjusted to a conditional raise of gross proceeds of approximately £2.6 million, by way of the issue of 9,331,888 Placing Shares at the Placing Price of 28 pence per Placing Share (the "Revised Placing"). The Company plans to use the net proceeds from the Revised Placing in the same manner as previously indicated; to continue expansion of real-money Regulated Gaming and Simulated GamingTM opportunities in the US and for working capital and general business development purposes. The Revised Placing remains conditional upon Admission. Applications have been made for 9,331,888 Placing Shares to be admitted to trading on AIM and the ESM and it is expected that dealings in these shares will commence on 8 April 2016. The Enlarged Issued Share Capital will be 65,301,924 ordinary shares of £0.01 each.

That's another reason to like this company The Smurfits are no mugs. At this price I wouldn't be surprised if one of the big companys came knocking on the door!

Is the turnaround year for this company imho. Look at all the new contracts that are income generating in 2016 Their CEO moved himself and his family to Las vegas to promote the company. Directors have a lot of skin in the game especially after last years results and recent placing. Rresults due on 25/04/16 and expect the good news to keep rolling in!

The market is huge at $3bn! GameAccount Network, the gaming software firm headed by Dermot Smurfit Junior, has signed a multi-year agreement with an unnamed “major” US casino operator to provide simulated gaming services. GAN said the new client is “the operator of a major established casino property generating in excess of $500m (€446m) in gross gaming revenues annually”. According to GAN, the new addition is now the tenth major US casino operator to nominate it and its Simulated Gaming software as the preferred model for launching online. The firm has been providing simulated gaming software to the social casino gaming market since the beginning of 2014. The software will be operated by GameSTACK internet gaming system deployed in Las Vegas Nevada and is expected to go live across web and mobile in later this year. GAN’s simulated gaming is an internet gaming service designed specifically for land-based US casinos, offering a gaming-as-entertainment consumer website and mobile apps that include over 200 casino slot and table games. GAN CEO Dermot Smurfit said the casino with which GAN has completed the deal “will be disclosed following completion of the regulatory approval process, a necessary feature of the highly regulated environment GAN’s clients operate within”. According to GAN, its simulated gaming monetises internet traffic to existing websites operated by land-based US casinos with average revenue per daily active user of $2.75 in 2014 and $2.82 in H1 2015, as against an original estimate of $0.60. Casino operators in the US report that up to 50% of their surveyed casino patrons are already engaged in playing Social Casinos on Facebook, a market that is estimated to be worth $3.3bn (€2.95bn) annually.

Somebody has to be first! I think this is mistaken for the old Game retail group Just read the RNS and make your own mind up.Don't worry about how posts are on a BB LOL!

at the mo

London & Dublin | March 29, 2016: GameAccount Network plc (“GAN” or the “Company”), an award-winning developer and supplier of enterprise-level B2B Internet gaming software, services and online gaming content in the United States, announces it has signed a multi-year agreement with an undisclosed major US casino operator (“Client”) for the launch of Simulated Gaming™, pending regulatory approval. Highlights Consistent with other GAN clients in the US, the new Client is the operator of a major established casino property generating in excess of $500m in gross gaming revenues annually. The Client’s property is situated in a new US State, continuing GAN’s State-by-State approach to the US market and ensures continuing access to the lucrative North Eastern regional social casino gaming market where GAN has unique experience operating Simulated Gaming™ since January 2014. Tenth major US casino operator to nominate GAN and Simulated Gaming as the preferred model for launching online, delivering true convergence between real money land-based gaming and online Simulated Gaming proven to increase on-property patron visitation. The Simulated Gaming™ offering will be operated from an instance of the GameSTACK™ Internet gaming system deployed in Las Vegas Nevada and is expected to go live across web and mobile in the second half of 2016. GAN’s US-patented iBridge Framework™ will link the GameSTACK™ Internet gaming system to the Client’s land-based casino management system. Simulated Gaming™ is an innovative Internet gaming service designed by GAN specifically for land-based US casinos, offering a gaming-as-entertainment consumer website and mobile apps that include over 200 casino slot and table games, including poker, backgammon, gin rummy, poker dice and blackjack tournaments. Dermot Smurfit, CEO of GAN commented: “GAN’s market-leading Simulated Gaming experience has been selected for the tenth time by a major US casino operator who’s identity will be disclosed following completion of the regulatory approval process, a necessary feature of the highly regulated environment GAN’s clients operate within. Our patented capability linking casino loyalty programs to our Simulated Gaming experience is expected to materially strengthen the Client’s existing patron relationships in an increasingly competitive regional market.”

Not showing on LSE? From what I have read plenty of upside here!

Keep on coming This companies future has been totally de risked and it is ready to exploit the opportunities that are coming in china!

(ShareCast News) – The People’s Operator finally jumped on the 4G bandwagon on Tuesday, taking the wraps off its SIM-only contract plan. Costing £6.99 per month, the AIM-traded mobile virtual network operator (MVNO) – which piggy-backs on EE’s mobile network – said the new plan would allow its customers to donate 10% of their bill to a charity of their choice, as with its existing plans. The plan includes 2GB of mobile data, 600 UK minutes and unlimited standard text messages. “I’m really excited about the introduction of our first UK 4G plan. This is another important milestone on our journey to help people use their mobile to make a big difference,” said CEO and co-founder of The People’s Operator, Mark Epstein. “Now, even more people can save when they switch to TPO and, at the same time, support a cause they choose.” At least someone else bought in with me at 32! LOL

Yep moving with every buy! Risk has been removed with online lottery suspension to be lifted and nasdaq listing to come! GL